65,437 trials
Peripheral Artery Disease
Primary: Laser Success — 34.7 percent reduction — p=0.001
Metabolic Syndrome · Morbid Obesity
Primary: Components of Metabolic Syndrome (Body Mass Index) — 44.9; 44.5 Kg/m2 — p=0.79
Hypertension
Primary: Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks). — -3.3; -9.3; -7.7; -13.9 mm Hg
Type 2 Diabetes · Hyperlipidemia
Primary: Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint — -0.31; -0.65; -0.56 % change HbA1c — p=0.0234
Type 2 Diabetes Mellitus
Primary: Treatment-emergent Antibody Status (Maximum Titer Level Experienced) — 15; 0; 0; 0 Participants
Submassive Pulmonary Embolism
Primary: Number of Participants With Major Bleeding Events — 1; 0; 0; 0 participants
Healthy
Primary: Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days — 0.1; 0.4 units on a scale
End-Stage Renal Disease
Primary: Long Dwell Ultrafiltration — 2167 milliliters
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
Essential Hypertension
Primary: Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16 — -11.16; -9.13; -8.10; -5.66 mm Hg — p=<0.0001
Urologic Neoplasms
Primary: Best Overall Tumor Response — 2; 13; 13; 1 participants
Mucopolysaccharidosis I · Hurler Syndrome · Hurler-Scheie Syndrome
Primary: Safety Evaluation — 16; 4; 5; 3 participants
Mucopolysaccharidosis I · Hurler's Syndrome · Hurler-Scheie Syndrome
Primary: Change From Baseline to Week 182 in Percent Predicted Forced Vital Capacity (FVC) — 51.0; 48.4; 47.7; 47.2 percent predicted FVC
Fabry Disease
Primary: Globotriaosylceramide (GL-3) Clearance in Capillary Endothelium in the Skin — 2; 14; 5; 0 patients
Kidney Failure, Acute
Primary: Number of Participants Who Had AKI (Acute Kidney Injury) — 3; 10 participants